Division of Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Curr HIV/AIDS Rep. 2012 Jun;9(2):132-8. doi: 10.1007/s11904-012-0111-2.
With effective treatment of HIV-1, hepatitis C virus (HCV) has become increasingly recognized as a major cause of morbidity and mortality in this population. Rapid progression of liver disease and cirrhosis has been documented in HIV/HCV co-infected individuals, particularly with lower CD4-counts (< 200/μL). Therefore, HCV treatment has become a priority for many clinicians, despite the presence of many. An important issue among HIV/HCV co-infected patients is the selection of antiretroviral therapy (ART) during treatment with pegylated interferon, ribavirin (RBV), plus new HCV protease inhibitors. Extensive drug-drug interactions (DDI) and overlapping drug-associated adverse events can impact the outcome of HCV therapy. In this review, we focus on the important data and studies regarding optimizing antiretroviral regimens before starting HCV treatment in HIV/HCV co-infected patients to increase the chance of sustained virologic response (SVR).
随着 HIV-1 的有效治疗，丙型肝炎病毒 (HCV) 已成为该人群发病率和死亡率的主要原因。在 HIV/HCV 合并感染个体中，已记录到肝脏疾病和肝硬化的快速进展，尤其是 CD4 计数较低（<200/μL）的个体。因此，尽管存在许多因素，HCV 治疗已成为许多临床医生的优先事项。HIV/HCV 合并感染患者的一个重要问题是在使用聚乙二醇干扰素、利巴韦林 (RBV) 和新型 HCV 蛋白酶抑制剂治疗期间选择抗逆转录病毒治疗 (ART)。广泛的药物相互作用 (DDI) 和重叠的药物相关不良事件会影响 HCV 治疗的结果。在这篇综述中，我们重点介绍了在开始 HIV/HCV 合并感染患者的 HCV 治疗之前优化抗逆转录病毒方案的重要数据和研究，以提高持续病毒学应答 (SVR) 的机会。
